Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Incyte

< Previous 1 2 3 4 5 6 Next >
News headline image
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
From Incyte
Via Business Wire
Tickers INCY
News headline image
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Tickers INCY
News headline image
Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
From Incyte
Via Business Wire
Tickers INCY
News headline image
Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
From Incyte
Via Business Wire
Tickers INCY
News headline image
New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Report Third Quarter Financial Results
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Tickers INCY
News headline image
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
From Incyte
Via Business Wire
Tickers INCY REPL
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.